Heidelberg Pharma AG
WILEX AG: Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pharma collaborate to create improved cancer therapeutics
DGAP-News: WILEX AG / Key word(s): Alliance PRESS RELEASE Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pharma collaborate to create improved cancer therapeutics – Companies will combine Heidelberg Pharma’s proprietary Antibody Targeted Amanitin Conjugates (ATAC) technology with APC’s proprietary site-specific protein modification technology Munich, Germany / Vancouver, Canada, 14 June 2016 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) and the Advanced Proteome Therapeutics Corporation, (TSX:V APC) today announced that Heidelberg Pharma GmbH, a subsidiary of WILEX AG, entered into a partnership with the Canadian APC to create a new generation of antibody-drug conjugates (ADCs). The companies will test combining APC’s proprietary site-specific protein modification technology and Heidelberg Pharma’s proprietary ATAC technology in order to generate a cancer therapeutic with enhanced characteristics that can also serve as a prototype for a new generation of antibody-drug conjugates (ADCs). “We are delighted to work with APC on the next generation of cancer therapies using APC’s approach which might broaden the scope of coupling methods for our ATAC technology”, commented Andreas Pahl, CSO of WILEX AG and Heidelberg Pharma GmbH. Allen Krantz, Founder and CEO of APC added: “The application of our site-specific technology to Heidelberg Pharma’s novel payload has the potential to result in examples of more homogeneous and more effective ADCs than have been available to date, while giving rise to a new type of antibody-drug conjugate with substantial appeal to the industry.” Demonstrable success in the milestone-driven research, using a combination of both technologies, provides a basis for the companies to work towards taking an eligible therapeutic product candidate into clinical studies. Heidelberg Pharma’s aim and expertise is in making the compound Amanitin available as a new cancer therapy. Amanitin has a unique biological mode of action which could be used as the basis for developing highly effective, innovative drugs. Selective treatment of tumours using cytotoxic payloads like Amanitin via specific antibody-drug conjugates could enable much more effective therapy than existing drugs. Heidelberg Pharma is building a pipeline of ATAC product development candidates alone or with partners. About APC Company Contact
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.
2016-06-14 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | WILEX AG | |
Grillparzerstr. 18 | ||
81675 München | ||
Germany | ||
Phone: | +49 (0)89 41 31 38 – 0 | |
Fax: | +49 (0)89 41 31 38 – 99 | |
E-mail: | info@wilex.com | |
Internet: | www.wilex.com | |
ISIN: | DE000A11QVV0 | |
WKN: | A11QVV | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart | |
End of News | DGAP News Service |